Jeremy Paul Cetnar, MD, MSHPR | Lung ...

Dr. Jeremy P. Cetnar

Claim this profile

Oregon Health and Science University

Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
11 reported clinical trials
23 drugs studied

Area of expertise

1Non-Small Cell Lung Cancer
Jeremy P. Cetnar has run 9 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
PD-L1 positive
2Lung Cancer
Jeremy P. Cetnar has run 9 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
RET positive

Affiliated Hospitals

Image of trial facility.
Oregon Health And Science University
Image of trial facility.
OHSU Knight Cancer Institute

Clinical Trials Jeremy P. Cetnar is currently running

Image of trial facility.

Radiation + Immunotherapy

for Non-Small Cell Lung Cancer

This phase II trial studies the side effects of radiation therapy followed by atezolizumab in treating patients with stage II or III non-small cell lung cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more cancer cells and have fewer side effects. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to test the safety and effectiveness of radiation therapy followed by atezolizumab and find out what side effects, if any, it has on patient's non-small cell lung cancer.
Recruiting1 award Phase 239 criteria
Image of trial facility.

Targeted Therapy Screening

for Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria

More about Jeremy P. Cetnar

Clinical Trial Related6 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Jeremy P. Cetnar has experience with
  • Pembrolizumab
  • Atezolizumab
  • Ramucirumab
  • NT-I7
  • Carboplatin
  • Cisplatin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Jeremy P. Cetnar specialize in?
Is Jeremy P. Cetnar currently recruiting for clinical trials?
Are there any treatments that Jeremy P. Cetnar has studied deeply?
What is the best way to schedule an appointment with Jeremy P. Cetnar?
What is the office address of Jeremy P. Cetnar?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security